PALI
NASDAQ · Biotechnology
Palisade Bio Inc
$1.85
+0.04 (+2.21%)
Open$1.82
Previous Close$1.81
Day High$1.85
Day Low$1.81
52W High$2.86
52W Low$0.53
Volume—
Avg Volume2.69M
Market Cap317.65M
P/E Ratio—
EPS$-4.92
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+137.8% upside
Current
$1.85
$1.85
Target
$4.40
$4.40
$2.36
$4.40 avg
$4.89
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 116.39M | 123.33M | 94.21M |
| Net Income | 12.19M | 12.43M | 9.10M |
| Profit Margin | 10.5% | 10.1% | 9.7% |
| EBITDA | 16.58M | 20.40M | 14.08M |
| Free Cash Flow | 11.50M | 12.12M | 8.26M |
| Rev Growth | -3.2% | +20.3% | +7.0% |
| Debt/Equity | 0.59 | 0.58 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $213.76 | +2.08% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $330.33 | -0.13% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $130.28 | -0.17% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $429.32 | -1.15% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $641.69 | +1.81% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $293.86 | -0.15% | 66.6 | 38.43B |